Kornimate/medical-research-clean huggingface dataset:
retinal detachment - demographic and clinical survey

Conditions: Rhegmatogenous Retinal Detachment

Summary: background: rhegmatogenous retinal detachment is an ophthalmic emergency that, without surgical repair, often leads to blindness. the incidence is about 1/10000/year. the leading causes are myopia and aging which cause retinal tears often resulting in retinal detachment. patients commonly experience photopsia, floaters, and peripheral visual field loss. two different general surgical treatment options exist for retinal detachment; scleral buckling or vitrectomy. however, the precise indications for each approach have not been well established. correct classification of the retinal detachment is important. the first step is to decide whether an intra- or extra-ocular surgical approach is more appropriate. simple rhegmatogenous retinal detachments are usually treated extraocularly with scleral buckling surgery, whereas more complicated cases require intraocular primary pars plana vitrectomy and one or more of gas, silicone oil, laser therapy, or cryotherapy. study objectives: the purpose of this study is to evaluate different surgical techniques for the treatment of retinal detachment. data relating to retinal status before treatment, surgical treatment, post-operative anatomy and visual acuity, post-operative oct, and intra- and post-operative complications will be collected. vitreous cytokines will also be analyzed to monitor intravitreal inflammation as a result of retinal detachment.


Eligibility criteria:
inclusion criteria: patients who received surgery due to retinal detachment between january 2008 and decemebr 2012. surgery was performed by either ass.prof.pd.dr. stefan sacu or prof.dr. michael georgopoulos exclusion criteria: if patients had prior vitrectomy or scleral buckel. if patients had no adequate follow-up.
patient registry: partial breast irradiation

Conditions: Breast Cancer

Summary: this is an aurora health care system registry of patients receiving accelerated partial breast irradiation and external beam.


Eligibility criteria:
inclusion criteria: * aurora patients who decide to undergo pbi treatment in the next 5-years or who have had pbi treatment in the last ten-years. all such patients are female. exclusion criteria: * patients not seen in an aurora facility

Keywords: patients receiving irradiation device external beam
use of wharton jelly in diabetic nephropathy

Conditions: Diabetic Nephropathies

Summary: wharton jelly derived mesenchymal stem cells will be injected in the renal parenchyma of patients with diabetic nephropathy

mesenchymal stem cells (mscs) are to be isolated from umbilical cord wharton's jelly obtained after normal full term delivery. samples will be tested for any bacterial or fungal growth as well as endotoxin and mycoplasma. the specific markers for mscs identification will be analyzed by flow cytometry. cell suspension will then be injected in the renal parenchyma of patients diagnosed with diabetic nephropathy.

Eligibility criteria:
inclusion criteria: * willing and able to provide written informed consent. * type 2 diabetes mellitus (dm) for ≥ 3 years. * estimated gfr (egfr) 15-45 ml/min/1.73 m2 by the chronic kidney disease epidemiology collaboration (ckd-epi) equation on 2 or more consecutive measurements at least 30 days apart within the past 6 months, confirmed by isotope kidney scan. * urine protein-to-creatinine ratio (upcr) ≥ 500 mg/mmol (in spot urine or in 24 hour urine collection) confirmed twice over a period of 6 months. * ultrasonographic kidney measurements ≥ 10 cm (for both kidneys). exclusion criteria: * patients with uncontrolled hyper or hypo tension; (systolic pressure \>160, \ 100) on two different occasions. * poor diabetic control: hemoglobin a1c (hba1c) \> 10%. * new use of hypoglycemic, antihypertensive and/or lipid lowering agent within the past 6 months. * increase in the dose of anti-hypertensive and/or hypoglycemic agent of the previous dose within the past 3 months. * current fasting total cholesterol \>300 mg/dl. * current fasting total triglycerides \>400 mg/dl. * history of any cardiovascular events in the past 6 months. * pregnancy or lactating. * positive screening test for infectious diseases as per baseline work up. * history of kidney transplant * systemic autoimmune disease. * receiving immunosuppressant medications. * patients with glomerulonephritis or any non-dm related kidney disease. * patients with any coagulation disorder.

Keywords: diabetes nephropathy kidney parenchyma wharton jelly mesenchymal stem cells
rct of the effect of uvulopalatopharyngoplasty compared to expectancy in patients with obstructive sleep apnea

Conditions: Obstructive Sleep Apnea Syndrome

Summary: hypothesis:pharyngeal surgery (uppp) reduces significantly the nightly respiratory breathing pauses (apnoeas-hypopnoeas) and improves the daytime symptoms compared to expectancy for 6 months in patients with osas. background: obstructive sleep apnea syndrome (osas) is associated with an increased risk of poor sleep quality, excessive daytime sleepiness and prolonged reaction time, which can elevate the risk for traffic accidents. increased morbidity and three to four times increased mortality in these patients are well documented, mainly in the cardiovascular field. pharyngeal surgery, i.e. uvulopalatopharyngoplasty (uppp) opens up the airway and was the predominant treatment for osas worldwide before continuous positive airway pressure (cpap) devices became widely available in the 1990s. since then, the main treatment for osas has been cpap, but an increasing number of patients are also treated with mandibular retaining device (mrd). uppp as treatment for osas has been performed for 30 years. the evidence-grade for the efficacy has so far been very low, and the side-effects and complication rate has raised the question whether there is a place for surgical treatment of osas. however, the compliance for cpap and dental devices are quite low (50-60%), leaving a lot of patients untreated if surgery is not offered. rct uppp is still missing and called for.


Eligibility criteria:
inclusion criteria: apnéhypopnéindex, ahi \>14,9 daytime sleepiness w epworth sleepiness scale, ess\> 7 sleepy during daytime 3-5 times per week or more bodymassindex, bmi \< 36,0 friedman staging system of tonsil size and tongue: i and ii patients w friedman stage i and bmi \< 30,0 could be directly included if patient positive and no contra-indications for surgery. all others should be failure of cpap and mrd before inclusion. exclusion criteria: other osas treatment during study, i.e., patient is clinically severely deteriorated. negative to surgery night-shift worker friedman stage iii or iv morbid obesity bmi \>35,9 severe psychological or neurological disease asa class \>3 severe lung- or heart disease (not applicable for hypertension, nor stroke or mi more than after 2 years). insufficient knowledge in swedish language (important for filling in questionnaires) dangerous in traffic while driving severe nasal congestion (can be included after successful treatment) previous tonsillectomy -
management of diabetic patients with telemedicine in the context of the covid-19 epidemic

Conditions: Diabetes; Covid-19

Summary: since the end of february 2020, covid-19 infection has spread widely in france, particularly in the east region, with on march 25th, 2020, 5,479 infected patients and 407 deceased patients, including 256 in alsace. among the hospitalized patients reported in the initial chinese studies, 48% had co-morbidity, particularly diabetes or cardiovascular disease. covid-19 infection does not appear to be more common in diabetic patients, but infected diabetics have more severe forms. the prevalence of diabetes is high in alsace affecting 6.5% of the population against 4.6% in france. du to health containment measures, asymptomatic diabetic patients can no longer come to the clinic in hospital for their consultation. however, in the current epidemiological context, maintaining optimal glycemic control is fundamental since some of diabetic patients will have covid-19 infections. furthermore, the sedentary lifestyle and snacking linked to the confinement period will contribute to a glycemic imbalance in some patients. telemedicine, and in particular teleconsultation, which until now has been very uncommon in the management of diabetic patients, represents a very interesting alternative for monitoring these patients and maintaining satisfactory metabolic control during the current period of confinement and covid-19 epidemic.


Eligibility criteria:
inclusion criteria: * adult diabetic patient (type 1,2, mody, secondary, post transplantation) followed by diabetology consultation at the hospital or by a liberal diabetologist * subject affiliated to a social health insurance * subject able to understand the objectives of the research * subject who expressed his non opposition to the research exclusion criteria: * pregnant woman * patients with acute complications (foot ulcer, post stroke, post idm) * cancer or life expectancy of less than 6 months * inability to provide informed information to the subject (subject in an emergency, difficulty of understanding for the subject, etc.) * subject under judicial protection * subject under guardianship or curatorship

Keywords: diabetes telemedicine covid-19 epidemic glucose control
anti-hiv medications for people recently infected with hiv

Conditions: HIV Infections

Summary: it is not known if anti-hiv treatment for recently infected patients improves long-term patient prognosis. the purpose of this study is to determine if a one year course of anti-hiv medications slows progression of hiv disease in adults recently infected with hiv. study hypothesis: a one-year course of haart administered during acute or early seroconversion may slow the progression of hiv infection.

although some doctors favor starting anti-hiv treatment as soon as possible after patients learn they are infected, it is not known if treatment for recently infected patients results in slower progression of hiv disease. this study will compare the virologic outcomes of recently infected adults who receive highly active antiretroviral therapy (haart) with those who receive no treatment. this study will also compare the effects of treatment on patients who enroll within 3 months of seroconversion (acute seroconverters) with patients who enroll within 3 to 12 months of seroconversion (early seroconverters). this study will last at least 3 years. participants will be randomly assigned to one of two groups. group 1 will receive haart for 1 year; group 2 will receive no treatment. there will be at least 20 study visits over the 3-year study period. blood collection will occur at all study visits. a physical exam, medical and medication history, and risk behavior assessment will occur at most visits; participants will also be asked to complete an adherence questionnaire at most visits.

Eligibility criteria:
inclusion criteria: * documented acute or recent hiv infection (infected in the past 12 months) as defined in the study protocol * antiretroviral naive. participants who have taken antiretrovirals for postexposure prophylaxis are eligible for this study. * able to swallow tablets or capsules * willing to use acceptable forms of contraception exclusion criteria: * physician unable to design a potentially effective haart regimen based on results of genotypic resistance testing * two cd4 counts of less than 350 cells/mm3 obtained at least 7 days apart within 30 days of study entry * viral load less than 5,000 copies/ml within 30 days of study entry in participants who have been infected with hiv-1 for more than six months prior to study entry * use of systemic cancer chemotherapy, systemic investigational agents, specific antiretroviral medications, or immunomodulators (growth factors, systemic corticosteroids, hiv vaccines, immune globulin, interleukins, interferons) within 30 days prior to study entry * current alcohol or drug use that, in the opinion of the investigator, would interfere with the study * serious illness requiring systemic treatment or hospitalization until participant either completes therapy or is clinically stable on therapy for at least 7 days prior to study entry * currently involuntarily incarcerated for treatment of either a psychiatric or physical (e.g., infectious disease) illness * pregnancy or breastfeeding

Keywords: hiv acute/early seroconverters acute infection treatment naive primary hiv infection
osteopathic manipulative treatments and neurogenic bowel dysfunction in patients with spinal cord injuries.

Conditions: Spinal Cord Injuries

Summary: studies based on the relationship between osteopathic manipulative treatment (omt) and the gastrointestinal system have been conducted in patients with constipation with irritable bowel syndrome (ibs), and in children with infantile cerebral palsy. for ibs patients, omt can facilitate visceral vascularization and restore the physiological elasticity and motility of the viscera, and of the peritoneal structures around the viscera. the study also focused on the effects of omt on women and constipated children, indicating an improvement in the stool consistency, reduction in the symptoms of constipation, the severity of the constipation, and in the use of laxative drugs. in patients with spinal cord injury (sci), the secondary health disorders include the alteration of gastric acid secretion, abnormal colonic myenteric activity, and neurogenic bowel dysfunction (nbd). patients with nbd present loss or absence of normal bowel function. about 80% of sci is accompanied by nbd resulting in a lower quality of life caused by loss of independence, sense of embarrassment, mental disorder, social isolation. conservative treatments for nbd after sci include oral laxatives, enemas, retroanal trans-grade irrigation and digital anorectal stimulation. these treatments are mainly focused on promoting intestinal faecal evacuation and on strengthening the anal sphincter to improve bowel function. there are no studies that investigate the effects of omt on patients with sci, however, several studies have already showed the effects of omt on the nervous system, on the hemodynamic system, and on visceral motility. therefore, the starting hypothesis of this study is to use omt in order to improve the symptoms of nbd in subjects with sci, through a global omt


Eligibility criteria:
inclusion criteria: * age between 18 and 70 years old, * chronic spinal cord injury (more than six months between the spinal injury and the enrollment in the research), * injury classified per the asia impairment scale ais a, b, c or d localized at a cervical-dorsal level up to d10. exclusion criteria: * use of bowel emptying techniques such as retrograde trans-anal irrigation * presence of previous inflammatory intestinal diseases * metabolic or endocrinological dysfunctions, * pregnancy state * cognitive disorders.
a four-way cross-over study to compare the plasma concentrations of pf-02413873 after oral administration of several doses as suspension and as tablets.

Conditions: Healthy

Summary: the study compares the plasma concentrations of pf-02413873 after administration of several doses as suspension and as tablets


Eligibility criteria:
inclusion criteria: * healthy male and female volunteers. * female volunteers have to be of non-childbearing potential exclusion criteria: * evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at time of dosing). * any condition possibly affecting drug absorption (eg, gastrectomy). * a positive urine drug screen.

Keywords: dose response bioavailability study
clinical investigation of bleeding reduction efficacy on toothpaste containing 1.05% chitosan

Conditions: Bleeding Gum; Gingivitis

Summary: the purpose of this study is to assess the bleeding reduction efficacy of toothpaste containing 1.05% chitosan compared to a regular fluoride toothpaste, and compared to a toothpaste containing 67% bicarbonate.


Eligibility criteria:
inclusion criteria: 1. male or female subjects, aged 18-70, inclusive. 2. availability for the duration of the study. 3. ability to understand and willingness to read, and sign the informed consent form after the nature of the study has been fully explained to them. 4. willingness to comply with all study procedures and clinical examination schedules. 5. good general health (absence of any condition that, in the opinion of the study examiner, might constitute a risk to the subject while participating in the study. examples include heart problems, valve/hip replacements etc). 6. presence of a minimum of 20 natural teeth (excluding third molars) with facial and lingual scoreable surfaces. 7. have a mean modified gingival index (lobene) ≥ 2.5 at screening. 8. subjects reporting bleeding while routine toothbrushing. exclusion criteria: 1. pregnant or lactating. 2. use of tobacco products. 3. history of alcohol or drug abuse. 4. medical condition (especially, heart or liver problems, bleeding disorders, blood dyscrasias) or any current usage of medication that the investigator considers may compromise the subject safety, as well as, the quality of the study results. 5. medical condition which requires pre-medication prior to dental visits/procedures. 6. history of allergy to oral hygiene products. 7. use of anti-inflammatory, immunosuppressive, antimicrobial or anticoagulant drugs or antibiotics in the 30 days prior to the start of the study and during the course of the study. 8. ongoing use of medications known to affect the gingival tissues (i.e. calcium channel blockers, phenytoin, cyclosporine). 9. presence of orthodontic bands or removable partial denture(s). 10. tumor (s) of the soft or hard tissues of the oral cavity. 11. five or more carious lesions requiring immediate restorative treatment. 12. more than 2 periodontal pockets (\>4mm deep) with bleeding on probing. 13. any gingival condition like hyperplasia or overgrowth, that would cause difficulty in clinical assessment. 14. participation in any other clinical study with an oral care indication or test panel within 30 days prior to the start of the study. 15. existing medical condition which prohibits the subject from not eating or drinking for periods of up to 2 hours.
artificial intelligence to solve the missing of gastric cancer (aiming)

Conditions: Gastric Cancer

Summary: our aiming project comprises four core work packages (wps): wp1. nation-level randomized controlled trial; wp2. development of an innovative ai tool; wp3. novel microsimulation modelling; wp4. patient inclusion. the nation-level multi-center tandem randomized controlled trial (wp1) will contribute to a better understanding of how the real-time ai algorithm can reduce miss rate of early gastric cancer and dysplasia during gastroscopy. moreover, the innovation project will contribute to development of a novel ai tool (wp2) that can stratify the risk of gastric cancer by identifying in vivo precancerous conditions. furthermore, a microsimulation modelling will allow us to predict how the use of ai can prevent gastric cancer and affect cost and patients' burdens. the assessment of the balance between benefits and harms is quite crucial especially for this type of medical device because the value of innovative tools is sometimes overestimated due to stakeholders' enthusiasm (wp3). finally, we will take care of patients' perspective throughout the study project by including patient organization in both wp1, 2, and 3 (wp4).


Eligibility criteria:
inclusion criteria: * all \>60 years-old patients undergoing upper-gastrointestinal (gi) endoscopy for selected indications at high-risk of gastric cancer.. exclusion criteria: * contraindications to upper-gi endoscopy. * contraindications to biopsy. * active upper-gi bleeding or urgent upper-gi endoscopy. * patients with previous upper-gi surgery involving the stomach. * patients who were not able or refused to give informed written consent.
transcutaneous electrical nerve stimulation for tissues perfusion

Conditions: Renal Function Disorder; Critical Illness; Critical Illness Myopathy

Summary: the aim of this study is to determine the effect of transcutaneous electrical nerve stimulation in mechanically ventilated patients on the lower limb and renal tissue perfusion.


Eligibility criteria:
inclusion criteria: * recently intubated patient. * adult and both gender. * hemodynamic stability exclusion criteria: * vascular diseases * diabetic patients * patients who receive vasoactive drugs * patients with varicose vein * systemic scoliosis
atrial fibrillation, stroke, and bleeding in patients undergoing aortic biovalve implantation

Conditions: Atrial Fibrillation; Stroke; Transient Ischemic Attack; Bleeding; Aortic Stenosis

Summary: the primary purpose of the fin-bioavr registry is to assess the incidence of af, strokes and major bleeding events in patients undergoing aortic valve replacement. this retrospective multicenter registry will include 850 patients with aortic valve replacement using bioprosthesis.


Eligibility criteria:
inclusion criteria: * patients undergoing aortic valve bioprosthesis implantation exclusion criteria: * mechanical heart valves in any position
hypoglycemia and autonomic nervous system function- b2

Conditions: Hypoglycemia; Type2 Diabetes

Summary: we will study the effect of hypoglycemia (low blood sugar) on baroreflex sensitivity in participants with well controlled type 2 diabetes.

participants are admitted for two days and two nights to an inpatient clinical research center for performance of study procedures. on day 1, two hyperinsulinemic hypoglycemic (50 mg/dl) clamps are performed - an am clamp from about 9 to 11 am and a pm clamp from about 1 to 3 pm.. modified oxford procedures are performed in duplicate at five time points -- before the am clamp, during the am clamp, before the pm clamp, during the pm clamp, and the morning of day 2 (about 16 hrs after completion of the the pm clamp). the modified oxford procedure involves the sequential intravenous administration of nitroprusside and phenylephrine with assessment of blood pressure and heart rate by finapress. baroreflex sensitivity is the relationship of changes in heart rate to changes in blood pressure. .

Eligibility criteria:
inclusion criteria: * males and females age 18 to 55 years * type 2 diabetes mellitus controlled by diet, exercise and non-insulin glycemic control agents (metformin, thiazolidinediones, sulfonylureas, dipeptidyl peptidase-4 inhibitors, sodium-glucose co-transporter 2 inhibitors, alpha-glucosidase inhibitors or glucagon-like peptide-1 receptor agonist) or basal insulin at doses less than or equal to 0.3 units/ kg per day. exclusion criteria: * hemoglobin a1c \> 9% for type 2 diabetes * recurrent hypoglycemic episodes within the past month * bmi \ 42 (type 2 diabetes only) * pregnancy * lactation * clinically significant coronary artery, cerebrovascular, or peripheral vascular disease, or presence of systemic illness that might affect autonomic function. such illnesses include congestive heart failure, renal, pulmonary, hepatic disease, anemia, malignancies, untreated thyroid disease, and alcoholism. * current major depressive illness * in all subjects, any individuals on oral, injected, inhaled or topical corticosteroids within the last year or oral contraceptives within the past 3 months will be excluded. * known hypersensitivity to nitroglycerin, nitroprusside and/or phenylephrine. * blood pressure \> 160/100 mmhg (applies to participants with t2 diabetes) * creatinine \> 1.5 mg/dl * serum potassium \>5.2 mmol/l * estimated gfr \< 50 ml/min * use of viagra, cialis, and similar drugs within 72 hours of admission. * use of beta-blockers or mineralocorticoid receptor antagonists